These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 35901621)

  • 1. Longitudinal examination of perfusion and angiogenesis markers in primary colorectal tumors shows distinct signatures for metronomic and maximum-tolerated dose strategies.
    Mundo AI; Muhammad A; Balza K; Nelson CE; Muldoon TJ
    Neoplasia; 2022 Oct; 32():100825. PubMed ID: 35901621
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diffuse optical spectroscopic imaging reveals distinct early breast tumor hemodynamic responses to metronomic and maximum tolerated dose regimens.
    Tank A; Peterson HM; Pera V; Tabassum S; Leproux A; O'Sullivan T; Jones E; Cabral H; Ko N; Mehta RS; Tromberg BJ; Roblyer D
    Breast Cancer Res; 2020 Mar; 22(1):29. PubMed ID: 32169100
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diffuse reflectance spectroscopy to monitor murine colorectal tumor progression and therapeutic response.
    Mundo AI; Greening GJ; Fahr MJ; Hale LN; Bullard EA; Rajaram N; Muldoon TJ
    J Biomed Opt; 2020 Mar; 25(3):1-16. PubMed ID: 32141266
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of maximum-tolerated doses and low-dose metronomic chemotherapy on serum vascular endothelial growth factor and thrombospondin-1 levels in patients with advanced nonsmall cell lung cancer.
    Tas F; Duranyildiz D; Soydinc HO; Cicin I; Selam M; Uygun K; Disci R; Yasasever V; Topuz E
    Cancer Chemother Pharmacol; 2008 Apr; 61(5):721-5. PubMed ID: 17554539
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The potential clinical promise of 'multimodality' metronomic chemotherapy revealed by preclinical studies of metastatic disease.
    Kerbel RS; Shaked Y
    Cancer Lett; 2017 Aug; 400():293-304. PubMed ID: 28202353
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhanced antitumor and anti-angiogenic effects of metronomic Vinorelbine combined with Endostar on Lewis lung carcinoma.
    Qin RS; Zhang ZH; Zhu NP; Chen F; Guo Q; Hu HW; Fu SZ; Liu SS; Chen Y; Fan J; Han YW
    BMC Cancer; 2018 Oct; 18(1):967. PubMed ID: 30305062
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer.
    Pietras K; Hanahan D
    J Clin Oncol; 2005 Feb; 23(5):939-52. PubMed ID: 15557593
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhanced anti-tumor and anti-angiogenic effects of metronomic cyclophosphamide combined with Endostar in a xenograft model of human lung cancer.
    Wang R; Qin S; Chen Y; Li Y; Chen C; Wang Z; Zheng R; Wu Q
    Oncol Rep; 2012 Aug; 28(2):439-45. PubMed ID: 22641525
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metronomic chemotherapy following the maximum tolerated dose is an effective anti-tumour therapy affecting angiogenesis, tumour dissemination and cancer stem cells.
    Vives M; Ginestà MM; Gracova K; Graupera M; Casanovas O; Capellà G; Serrano T; Laquente B; Viñals F
    Int J Cancer; 2013 Nov; 133(10):2464-72. PubMed ID: 23649709
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metronomic chemotherapy enhances the efficacy of antivascular therapy in ovarian cancer.
    Kamat AA; Kim TJ; Landen CN; Lu C; Han LY; Lin YG; Merritt WM; Thaker PH; Gershenson DM; Bischoff FZ; Heymach JV; Jaffe RB; Coleman RL; Sood AK
    Cancer Res; 2007 Jan; 67(1):281-8. PubMed ID: 17210709
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synergistic antitumor effects of combination treatment with metronomic doxorubicin and VEGF-targeting RNAi nanoparticles.
    Kwak G; Jo SD; Kim D; Kim H; Kim MG; Kim K; Kwon IC; Kim SH
    J Control Release; 2017 Dec; 267():203-213. PubMed ID: 28823674
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-angiogenic properties of metronomic topotecan in ovarian carcinoma.
    Merritt WM; Danes CG; Shahzad MM; Lin YG; Kamat AA; Han LY; Spannuth WA; Nick AM; Mangala LS; Stone RL; Kim HS; Gershenson DM; Jaffe RB; Coleman RL; Chandra J; Sood AK
    Cancer Biol Ther; 2009 Aug; 8(16):1596-603. PubMed ID: 19738426
    [TBL] [Abstract][Full Text] [Related]  

  • 13. VEGFR2 heterogeneity and response to anti-angiogenic low dose metronomic cyclophosphamide treatment.
    Patten SG; Adamcic U; Lacombe K; Minhas K; Skowronski K; Coomber BL
    BMC Cancer; 2010 Dec; 10():683. PubMed ID: 21159176
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metronomic activity of CD44-targeted hyaluronic acid-paclitaxel in ovarian carcinoma.
    Lee SJ; Ghosh SC; Han HD; Stone RL; Bottsford-Miller J; Shen DY; Auzenne EJ; Lopez-Araujo A; Lu C; Nishimura M; Pecot CV; Zand B; Thanapprapasr D; Jennings NB; Kang Y; Huang J; Hu W; Klostergaard J; Sood AK
    Clin Cancer Res; 2012 Aug; 18(15):4114-21. PubMed ID: 22693353
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of acquired resistance to metronomic oral topotecan chemotherapy plus pazopanib after prolonged preclinical potent responsiveness in advanced ovarian cancer.
    Cruz-Muñoz W; Di Desidero T; Man S; Xu P; Jaramillo ML; Hashimoto K; Collins C; Banville M; O'Connor-McCourt MD; Kerbel RS
    Angiogenesis; 2014 Jul; 17(3):661-73. PubMed ID: 24569856
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metronomic chemotherapy and immunotherapy in cancer treatment.
    Chen YL; Chang MC; Cheng WF
    Cancer Lett; 2017 Aug; 400():282-292. PubMed ID: 28189534
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metronomic 5-fluorouracil, oxaliplatin and irinotecan in colorectal cancer.
    Fioravanti A; Canu B; Alì G; Orlandi P; Allegrini G; Di Desidero T; Emmenegger U; Fontanini G; Danesi R; Del Tacca M; Falcone A; Bocci G
    Eur J Pharmacol; 2009 Oct; 619(1-3):8-14. PubMed ID: 19695243
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Spica prunellae promotes cancer cell apoptosis, inhibits cell proliferation and tumor angiogenesis in a mouse model of colorectal cancer via suppression of stat3 pathway.
    Lin W; Zheng L; Zhuang Q; Zhao J; Cao Z; Zeng J; Lin S; Xu W; Peng J
    BMC Complement Altern Med; 2013 Jun; 13():144. PubMed ID: 23800091
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Decade of Experience in Developing Preclinical Models of Advanced- or Early-Stage Spontaneous Metastasis to Study Antiangiogenic Drugs, Metronomic Chemotherapy, and the Tumor Microenvironment.
    Kerbel RS
    Cancer J; 2015; 21(4):274-83. PubMed ID: 26222079
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase Ib study of capecitabine and ziv-aflibercept followed by a phase II single-arm expansion cohort in chemotherapy refractory metastatic colorectal cancer.
    Strickler JH; Rushing CN; Niedzwiecki D; McLeod A; Altomare I; Uronis HE; Hsu SD; Zafar SY; Morse MA; Chang DZ; Wells JL; Blackwell KL; Marcom PK; Arrowood C; Bolch E; Haley S; Rangwala FA; Hatch AJ; Nixon AB; Hurwitz HI
    BMC Cancer; 2019 Nov; 19(1):1032. PubMed ID: 31675952
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.